Anteris Technologies Global Corp. (ASX:AVR)
6.75
+0.42 (6.64%)
Dec 4, 2025, 4:10 PM AEST
ASX:AVR Revenue
Anteris Technologies Global had revenue of $429.00K USD in the quarter ending September 30, 2025, a decrease of -44.21%. This brings the company's revenue in the last twelve months to $2.14M, down -21.11% year-over-year. In the year 2024, Anteris Technologies Global had annual revenue of $2.70M, down -1.17%.
Revenue (ttm)
$2.14M
Revenue Growth
-21.11%
P/S Ratio
85.99
Revenue / Employee
$15.73K
Employees
136
Market Cap
278.08M AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.70M | -32.00K | -1.17% |
| Dec 31, 2023 | 2.74M | -384.72K | -12.33% |
| Dec 31, 2022 | 3.12M | -2.55M | -44.93% |
| Dec 31, 2021 | 5.66M | 203.73K | 3.73% |
| Dec 31, 2020 | 5.46M | -6.54M | -54.48% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Ramsay Health Care | 17.79B |
| Sonic Healthcare | 9.65B |
| Ansell | 3.06B |
| Cochlear | 2.34B |
| Regis Healthcare | 1.16B |
| Telix Pharmaceuticals | 1.01B |
| Neuren Pharmaceuticals | 218.86M |
Anteris Technologies Global News
- 17 days ago - Anteris Technologies (AVR) Reports Promising Results for DurAVR THV in Aortic Stenosis - GuruFocus
- 19 days ago - Sio Capital Management, LLC Reduces Stake in Anteris Technologies Global Corp - GuruFocus
- 5 weeks ago - Anteris Technologies (AVR) Reports Promising One-Year Results for DurAVR Heart Valve - GuruFocus
- 5 weeks ago - Anteris Technologies (AVR) Advances DurAVR Heart Valve Trial - GuruFocus
- 5 weeks ago - Anteris Technologies (AVR) to Present Key Clinical Outcomes at TCT 2025 - GuruFocus
- 5 weeks ago - L1-backed heart medtech Anteris Technologies rakes in $39m - The Australian Financial Review
- 7 weeks ago - Anteris Technologies (AVR) Gains Approval for Global Heart Valve Trial in Denmark - GuruFocus
- 2 months ago - Anteris Technologies (AVR) Reschedules Special Stockholders Meeting - GuruFocus